Lucas A M Ferreira

List of Publications by Year
in descending order

85 papers	2,247 citations	186265 28 h-index	254184 43 g-index
86 all docs	86 docs citations	86 times ranked	2916 citing authors

#	Article	IF	Citations
1	Memantine-Derived Schiff Bases as Transdermal Prodrug Candidates. ACS Omega, 2022, 7, 11678-11687.	3.5	2
2	Stepwise Protocols for Preparation and Use of Porcine Ear Skin for in Vitro Skin Permeation Studies Using Franz Diffusion Cells. Current Protocols, 2022, 2, e391.	2.9	3
3	Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes. Pharmaceutics, 2022, 14, 989.	4.5	14
4	Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model. Biomedicine and Pharmacotherapy, 2021, 133, 110936.	5.6	26
5	Efficacy of nanoemulsion with Pterodon emarginatus Vogel oleoresin for topical treatment of cutaneous leishmaniasis. Biomedicine and Pharmacotherapy, 2021, 134, 111109.	5.6	21
6	Doxorubicin-loaded pH-sensitive micelles: A promising alternative to enhance antitumor activity and reduce toxicity. Biomedicine and Pharmacotherapy, 2021, 134, 111076.	5.6	22
7	All-trans retinoic acid in anticancer therapy: how nanotechnology can enhance its efficacy and resolve its drawbacks. Expert Opinion on Drug Delivery, 2021, 18, 1335-1354.	5.0	7
8	Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies. Frontiers in Cardiovascular Medicine, 2021, 8, 690533.	2.4	4
9	Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice. Pharmaceutics, 2021, 13, 1021.	4.5	16
10	Nanostructured lipid carriers enhances the safety profile of tretinoin: in vitro and healthy human volunteersâ€™ studies. Nanomedicine, 2021, 16, 1391-1409.	3.3	5
11	4-Chlorophenylthioacetone-derived thiosemicarbazones as potent antitrypanosomal drug candidates: Investigations on the mode of action. Bioorganic Chemistry, 2021, 113, 105018.	4.1	8
12	Nanomedicine to deliver docosahexaenoic acid: potential applications to improve health. Nanomedicine, 2021, 16, 1549-1552.	3.3	2
13	Recent progress in micro and nano-encapsulation of bioactive derivatives of the Brazilian genus Pterodon. Biomedicine and Pharmacotherapy, 2021, 143, 112137.	5.6	11
14	pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects. Biomedicine and Pharmacotherapy, 2021, 144, 112373.	5.6	8
15	Nanotechnology in adjuvants and vaccine development: what should we know?. Nanomedicine, 2021, 16, 2565-2568.	3.3	4
16	Retinoic acid-loaded solid lipid nanoparticles surrounded by chitosan film support diabetic wound healing in in vivo study. Colloids and Surfaces B: Biointerfaces, 2020, 188, 110749.	5.0	53
17	Alpha-tocopheryl succinate improves encapsulation, pH-sensitivity, antitumor activity and reduces toxicity of doxorubicin-loaded liposomes. European Journal of Pharmaceutical Sciences, 2020, 144, 105205.	4.0	22
18	Ion Pair Strategy in Solid Lipid Nanoparticles: a Targeted Approach to Improve Epidermal Targeting with Controlled Adapalene Release, Resulting Reduced Skin Irritation. Pharmaceutical Research, 2020, 37, 148.	3.5	10

#	Article	IF	Citations
19	Co-delivery of doxorubicin, docosahexaenoic acid, and Î±-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity. Biomedicine and Pharmacotherapy, 2020, 132, 110876.	5.6	44
20	Novel self-nanoemulsifying drug-delivery system enhances antileukemic properties of all-trans retinoic acid. Nanomedicine, 2020, 15, 1471-1486.	3.3	6
21	Sclareol is a potent enhancer of doxorubicin: Evaluation of the free combination and co-loaded nanostructured lipid carriers against breast cancer. Life Sciences, 2019, 232, 116678.	4.3	26
22	Topical photodynamic therapy with chloroaluminum phthalocyanine liposomes is as effective as systemic pentavalent antimony in the treatment of experimental cutaneous leishmaniasis. Photodiagnosis and Photodynamic Therapy, 2019, 28, 210-215.	2.6	24
23	Nanoencapsulated retinoic acid as a safe tolerogenic adjuvant for intranasal vaccination against cutaneous leishmaniasis. Vaccine, 2019, 37, 3660-3667.	3.8	20
24	Sclareol-loaded lipid nanoparticles improved metabolic profile in obese mice. Life Sciences, 2019, 218, 292-299.	4.3	16
25	Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model. Molecular Imaging and Biology, 2018, 20, 437-447.	2.6	27
26	A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B. Journal of Drug Targeting, 2018, 26, 357-364.	4.4	29
27	Hyaluronic acid-coated nanoemulsions loaded with a hydrophobic ion pair of all-trans retinoic acid for improving the anticancer activity. Brazilian Journal of Pharmaceutical Sciences, 2018, 54, .	1.2	5
28	Improved Cytotoxic Effect of Doxorubicin by Its Combination with Sclareol in Solid Lipid Nanoparticle Suspension. Journal of Nanoscience and Nanotechnology, 2018, 18, 5609-5616.	0.9	10
29	Î±- Tocopherol succinate loaded nano-structed lipid carriers improves antitumor activity of doxorubicin in breast cancer models in vivo. Biomedicine and Pharmacotherapy, 2018, 103, 1348-1354.	5.6	40
30	Hydrophobic ion pairing as a strategy to improve drug encapsulation into lipid nanocarriers for the cancer treatment. Expert Opinion on Drug Delivery, 2017, 14, 983-995.	5.0	35
31	Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis. International Journal of Nanomedicine, 2016, 11, 2305.	6.7	17
32	Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis. International Journal of Nanomedicine, 2016, Volume 11, 3737-3751.	6.7	31
33	Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy. Biomedicine and Pharmacotherapy, 2016, 84, 252-257.	5.6	42
34	Solid lipid nanoparticles co-loaded with doxorubicin and Î±-tocopherol succinate are effective against drug-resistant cancer cells in monolayer and 3-D spheroid cancer cell models. International Journal of Pharmaceutics, 2016, 512, 292-300.	5.2	65
35	Metabolomics as a tool to evaluate the toxicity of formulations containing amphotericin B, an antileishmanial drug. Toxicology Research, 2016, 5, 1720-1732.	2.1	7
36	Technetium-99m-labeled doxorubicin as an imaging probe for murine breast tumor (4T1 cell line) identification. Nuclear Medicine Communications, 2016, 37, 307-312.	1.1	20

#	Article	IF	Citations
37	Evaluation of Antitumor Activity of Long-Circulating and pH-Sensitive Liposomes Containing Ursolic Acid in Animal Models of Breast Tumor and Gliosarcoma. Integrative Cancer Therapies, 2016, 15, 512-524.	2.0	15
38	Î±-Tocopherol succinate improves encapsulation and anticancer activity of doxorubicin loaded in solid lipid nanoparticles. Colloids and Surfaces B: Biointerfaces, 2016, 140, 246-253.	5.0	49
39	Improved In Vitro Antileukemic Activity of All-Trans Retinoic Acid Loaded in Cholesteryl Butyrate Solid Lipid Nanoparticles. Journal of Nanoscience and Nanotechnology, 2016, 16, 1291-1300.	0.9	25
40	Systemic administration of a nanoemulsion with tributyrin reduces inflammation in experimental colitis. European Journal of Lipid Science and Technology, 2016, 118, 157-164.	1.5	2
41	Alendronate-coated long-circulating liposomes containing 99mtechnetium-ceftizoxime used to identify osteomyelitis. International Journal of Nanomedicine, 2015, 10, 2441.	6.7	27
42	Nanostructured lipid carriers loaded with tributyrin as an alternative to improve anticancer activity ofall-transretinoic acid. Expert Review of Anticancer Therapy, 2015, 15, 247-256.	2.4	24
43	Nanoemulsions loaded with amphotericin B: A new approach for the treatment of leishmaniasis. European Journal of Pharmaceutical Sciences, 2015, 70, 125-131.	4.0	58
44	Determination of all-trans retinoic acid loaded in solid lipid nanoparticles by differential pulse voltammetry at glassy carbon electrode. Electrochimica Acta, 2015, 182, 929-934.	5.2	6
45	Solid Lipid Nanoparticles Loaded with Retinoic Acid and Lauric Acid as an Alternative for Topical Treatment of Acne Vulgaris. Journal of Nanoscience and Nanotechnology, 2015, 15, 792-799.	0.9	37
46	Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused byLeishmania(Viannia)braziliensis. Journal of Antimicrobial Chemotherapy, 2015, 70, dkv254.	3.0	8
47	Improved pharmacokinetics and enhanced tumor growth inhibition using a nanostructured lipid carrier loaded with doxorubicin and modified with a layer-by-layer polyelectrolyte coating. International Journal of Pharmaceutics, 2015, 495, 186-193.	5.2	19
48	Novel Nanostructured Lipid Carrier Co-Loaded with Doxorubicin and Docosahexaenoic Acid Demonstrates Enhanced in Vitro Activity and Overcomes Drug Resistance in MCF-7/Adr Cells. Pharmaceutical Research, 2014, 31, 1882-1892.	3.5	64
49	Pharmaceutical nanocarrier association with chondrocytes and cartilage explants: influence of surface modification and extracellular matrix depletion. Osteoarthritis and Cartilage, 2013, 21, 377-384.	1.3	20
50	New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. European Journal of Pharmaceutical Sciences, 2013, 48, 282-290.	4.0	95
51	Preparation, Physicochemical Characterization, and Cell Viability Evaluation of Long-Circulating and pH-Sensitive Liposomes Containing Ursolic Acid. BioMed Research International, 2013, 2013, 1-7.	1.9	47
52	Evaluation of Antitumor Activity and Development of Solid Lipid Nanoparticles of Metronidazole Analogue. Journal of Biomedical Nanotechnology, 2013, 9, 1939-1944.	1.1	6
53	Triphenylmethane Derivatives Have High In Vitro and In Vivo Activity against the Main Causative Agents of Cutaneous Leishmaniasis. PLoS ONE, 2013, 8, e51864.	2.5	7
54	Drug delivery systems for the topical treatment of cutaneous leishmaniasis. Expert Opinion on Drug Delivery, 2012, 9, 1083-1097.	5.0	50

#	Article	IF	Citations
55	Amphotericin B-Loaded Nanocarriers for Topical Treatment of Cutaneous Leishmaniasis: Development, Characterization, and <I>In Vitro</I> Skin Permeation Studies. Journal of Biomedical Nanotechnology, 2012, 8, 322-329.	1.1	42
56	Formation of ion pairing as an alternative to improve encapsulation and anticancer activity of all-trans retinoic acid loaded in solid lipid nanoparticles. International Journal of Nanomedicine, 2012, 7, 6011.	6.7	23
57	Evaluation of the Quality and Acceptability of Milk Drinks Added of Conjugated Linoleic Acid and Canola Oil and Produced in Pilot Scale. American Journal of Food Technology, 2012, 7, 736-745.	0.2	0
58	Preparation, characterization, and topical delivery of paromomycin ion pairing. Drug Development and Industrial Pharmacy, 2011, 37, 1083-1089.	2.0	8
59	Skin-healing activity and toxicological evaluation of a proteinase fraction from Carica candamarcensis. European Journal of Dermatology, 2011, 21, 722-730.	0.6	13
60	Comedolytic effect and reduced skin irritation of a new formulation of all-trans retinoic acid-loaded solid lipid nanoparticles for topical treatment of acne. Archives of Dermatological Research, 2011, 303, 513-520.	1.9	57
61	New insights into the mode of action of ultradeformable vesicles using calcein as hydrophilic fluorescent marker. European Journal of Pharmaceutical Sciences, 2010, 39, 90-96.	4.0	41
62	Reductions in Skin and Systemic Parasite Burdens as a Combined Effect of Topical Paromomycin and Oral Miltefosine Treatment of Mice Experimentally Infected with Leishmania (Leishmania) Tj ETQq0 0 0 rgBT /Overlock 10	3.2	29
63	Topical delivery andin vivoantileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. Journal of Liposome Research, 2010, 20, 16-23.	3.3	52
64	Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. Journal of Antimicrobial Chemotherapy, 2009, 64, 1234-1240.	3.0	25
65	Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. International Journal of Pharmaceutics, 2009, 381, 77-83.	5.2	105
66	Chapter 3 Physicochemical and Pharmacokinetic Characterization of Ultradeformable Vesicles using Calcein as Hydrophilic Fluorescent Marker. Behavior Research Methods, 2009, , 65-85.	4.0	1
67	Novel vesicular and particulate drug delivery systems for topical treatment of acne. Expert Opinion on Drug Delivery, 2008, 5, 665-679.	5.0	60
68	Characterization of a new solid lipid nanoparticle formulation containing retinoic acid for topical treatment of acne. Powder Diffraction, 2008, 23, S30-S35.	0.2	11
69	Fluconazol Method Validation by RP-HPLC for Determination in Biological Skin Matrices. Journal of Chromatographic Science, 2007, 45, 286-290.	1.4	9
70	Topical Delivery of Fluconazole: In Vitro Skin Penetration and Permeation Using Emulsions as Dosage Forms. Drug Development and Industrial Pharmacy, 2007, 33, 273-280.	2.0	34
71	Development of a new solid lipid nanoparticle formulation containing retinoic acid for topical treatment of acne. Journal of Microencapsulation, 2007, 24, 395-407.	2.8	53
72	Efficacy of 2,6-dichlorophenol lure to control Dermacentor nitens. Veterinary Parasitology, 2007, 147, 155-160.	1.8	7

#	Article	IF	Citations
73	Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis. Parasitology Research, 2007, 100, 1221-1226.	1.6	20
74	Mode of action of Î²-cyclodextrin as an absorption enhancer of the water-soluble drug meglumine antimoniate. International Journal of Pharmaceutics, 2006, 325, 39-47.	5.2	37
75	Characterization of Liposomes Containing 5-Fluorouracil in Hydrophilic Gel Using Atomic Force Microscopy. Microscopy and Microanalysis, 2005, 11, 62-65.	0.4	2
76	Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis. Acta Tropica, 2005, 93, 161-167.	2.0	32
77	Influence of the formulation type (o/w, w/o/w emulsions and ointment) on the topical delivery of paromomycin. BJPS: Brazilian Journal of Pharmaceutical Sciences, 2004, 40, 345-352.	0.5	3
78	In Vitro Skin Permeation and Retention of Paromomycin from Liposomes for Topical Treatment of the Cutaneous Leishmaniasis. Drug Development and Industrial Pharmacy, 2004, 30, 289-296.	2.0	69
79	PreparaÃ§Ã£o e caracterizaÃ§Ã£o de extratos glicÃ³licos enriquecidos em taninos a partir das cascas de Stryphnodendron adstringens (Mart.) Coville (BarbatimÃ£o). Revista Brasileira De Farmacognosia, 2002, 12, 27.	1.4	14
80	Combined Interleukinâ€12 and Topical Chemotherapy for Established Leishmaniasis Drastically Reduces Tissue Parasitism and Relapses in Susceptible Mice. Journal of Infectious Diseases, 2001, 183, 1646-1652.	4.0	13
81	Influence of lipophilic surfactant on the release kinetics of water-soluble molecules entrapped in a W/O/W multiple emulsion. Journal of Controlled Release, 1997, 45, 1-13.	9.9	121
82	In vitro percutaneous absorption of metronidazole and glucose: Comparison of o/w, w/o/w and w/o systems. International Journal of Pharmaceutics, 1995, 121, 169-179.	5.2	21
83	Vehicle influence on in vitro release of glucose: w/o, w/o/w and o/w systems compared. Journal of Controlled Release, 1995, 33, 349-356.	9.9	28
84	Vehicle influence on in vitro release of metronidazole: role of w/o/w multiple emulsion. International Journal of Pharmaceutics, 1994, 109, 251-259.	5.2	41
85	Nanostructured lipid carriers as a novel tool to deliver sclareol: physicochemical characterisation and evaluation in human cancer cell lines. Brazilian Journal of Pharmaceutical Sciences, 0, 57, .	1.2	3